The results showed that compared with normal tissues, the expression of mfap2 was higher in bladder cancer, brain and central nervous system cancer, breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, lymphoma, melanoma, myeloma, ovarian cancer, pancreatic cancer and sarcoma. This evidence concerns the gene MFAP2 and central nervous system cancer.